Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
LINC02566 (long intergenic non-protein coding RNA 2566), also known as LNC-Sox5, is a human long non-coding RNA approved by the HUGO Gene Nomenclature Committee and catalogued as HGNC:53606[1][4]. It is classified as a long non-coding RNA (lncRNA), a type of RNA molecule longer than 200 nucleotides that does not encode a protein. While other lncRNAs have been linked to various biological processes and diseases, there is currently no publicly available data describing the specific biological functions, interacting proteins or RNAs, disease associations, or drug interactions involving LINC02566. Its alias, LNC-Sox5, suggests a possible connection or regulatory relationship with the transcription factor SOX5, but no research studies have directly detailed this interaction or its role in pathology or therapy. Thus, LINC02566 should be considered a non-protein-coding RNA with no established function or therapeutic targeting status at this time[1][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Long intergenic non-protein coding RNA 2566 (LINC02566).